Bryce Point Capital LLC Acquires New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Bryce Point Capital LLC bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 44,063 shares of the company’s stock, valued at approximately $845,000. Bryce Point Capital LLC owned 0.06% of Viridian Therapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Loomis Sayles & Co. L P bought a new position in shares of Viridian Therapeutics in the fourth quarter worth about $26,845,000. Parkman Healthcare Partners LLC purchased a new position in shares of Viridian Therapeutics during the third quarter worth approximately $9,669,000. Victory Capital Management Inc. bought a new stake in shares of Viridian Therapeutics during the fourth quarter valued at approximately $7,868,000. Lord Abbett & CO. LLC purchased a new stake in shares of Viridian Therapeutics in the third quarter valued at approximately $8,917,000. Finally, Raymond James Financial Inc. bought a new position in Viridian Therapeutics in the fourth quarter worth approximately $6,015,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Royal Bank of Canada lifted their target price on Viridian Therapeutics from $44.00 to $47.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $27.00 price objective (down from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Needham & Company LLC reissued a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research report on Monday, December 16th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Viridian Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $35.70.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $13.07 on Thursday. The firm’s fifty day simple moving average is $16.44 and its two-hundred day simple moving average is $19.54. The firm has a market capitalization of $1.07 billion, a P/E ratio of -3.03 and a beta of 1.05. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. Analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.